Amgen Inc vs. Krystal Biotech, Inc. Common Stock
Amgen Inc (AMGN) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| AMGN | KRYS | |
|---|---|---|
| Market Cap | $239.32 billion | $10.16 billion |
| Revenue (TTM) | $38.09 billion | $440.48 million |
| Net Income (TTM) | $8.74 billion | $241.47 million |
AMGN leads on 3 of 3 size & scale factors.
Valuation
| AMGN | KRYS | |
|---|---|---|
| P/E Ratio | 26.94 | 42.23 |
| Price / Book | 20.48 | 7.48 |
| Price / Sales | 6.28 | 23.07 |
AMGN leads on 2 of 3 valuation factors.
Profitability
| AMGN | KRYS | |
|---|---|---|
| Net Margin | 22.95% | 54.82% |
| Return on Equity | 74.80% | 17.77% |
AMGN and KRYS split the profitability factors evenly.
Dividend
| AMGN | KRYS | |
|---|---|---|
| Dividend Yield | 2.32% | — |
| Payout Ratio | 62.61 | — |
AMGN and KRYS split the dividend factors evenly.
Risk & Sentiment
| AMGN | KRYS | |
|---|---|---|
| Short Interest | 1.66% | 0.11% |
KRYS leads on 1 of 1 risk & sentiment factors.
Dig deeper: AMGN overview, AMGN financials, KRYS overview, KRYS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.